Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
Klein G, Delmar P, Voyle N, Rehal S, Hofmann C, Abi-Saab D, Andjelkovic M, Ristic S, Wang G, Bateman R, Kerchner GA, Baudler M, Fontoura P, Doody R. Klein G, et al. Among authors: hofmann c. Alzheimers Res Ther. 2019 Dec 12;11(1):101. doi: 10.1186/s13195-019-0559-z. Alzheimers Res Ther. 2019. PMID: 31831056 Free PMC article.
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators. Ostrowitzki S, et al. Among authors: hofmann c. Alzheimers Res Ther. 2017 Dec 8;9(1):95. doi: 10.1186/s13195-017-0318-y. Alzheimers Res Ther. 2017. PMID: 29221491 Free PMC article. Clinical Trial.
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P; SCarlet RoAD Investigators. Ostrowitzki S, et al. Among authors: hofmann c. Alzheimers Res Ther. 2018 Sep 27;10(1):99. doi: 10.1186/s13195-018-0409-4. Alzheimers Res Ther. 2018. PMID: 30261916 Free PMC article.
A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
Portron A, Jordan P, Draper K, Muenzer C, Dickerson D, van Iersel T, Hofmann C. Portron A, et al. Among authors: hofmann c. Clin Ther. 2020 Jan;42(1):108-120.e1. doi: 10.1016/j.clinthera.2019.11.015. Epub 2019 Dec 26. Clin Ther. 2020. PMID: 31883703 Free article. Clinical Trial.
In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
Aldea R, Grimm HP, Gieschke R, Hofmann C, Lott D, Bullain S, Delmar P, Klein G, Lyons M, Piazza F, Carare RO, Mazer NA. Aldea R, et al. Among authors: hofmann c. Alzheimers Dement (N Y). 2022 Jun 6;8(1):e12306. doi: 10.1002/trc2.12306. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35676943 Free PMC article.
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
Joseph-Mathurin N, Llibre-Guerra JJ, Li Y, McCullough AA, Hofmann C, Wojtowicz J, Park E, Wang G, Preboske GM, Wang Q, Gordon BA, Chen CD, Flores S, Aggarwal NT, Berman SB, Bird TD, Black SE, Borowski B, Brooks WS, Chhatwal JP, Clarnette R, Cruchaga C, Fagan AM, Farlow M, Fox NC, Gauthier S, Hassenstab J, Hobbs DA, Holdridge KC, Honig LS, Hornbeck RC, Hsiung GR, Jack CR Jr, Jimenez-Velazquez IZ, Jucker M, Klein G, Levin J, Mancini M, Masellis M, McKay NS, Mummery CJ, Ringman JM, Shimada H, Snider BJ, Suzuki K, Wallon D, Xiong C, Yaari R, McDade E, Perrin RJ, Bateman RJ, Salloway SP, Benzinger TLS, Clifford DB; Dominantly Inherited Alzheimer Network Trials Unit. Joseph-Mathurin N, et al. Among authors: hofmann c. Ann Neurol. 2022 Nov;92(5):729-744. doi: 10.1002/ana.26511. Epub 2022 Oct 13. Ann Neurol. 2022. PMID: 36151869 Free PMC article.
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Wang G, Li Y, Xiong C, McDade E, Clifford DB, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Libre-Guerra JJ, McCullough A, Joseph-Mathurin N, Chen CD, Mummery C, Wendelberger BA, Gauthier S, Masellis M, Holdridge KC, Yaari R, Chatterjee S, Sims J, Delmar P, Kerchner GA, Bittner T, Hofmann C, Bateman RJ; DIAN‐TU Study Team. Wang G, et al. Among authors: hofmann c. Alzheimers Dement (Amst). 2022 Nov 3;14(1):e12367. doi: 10.1002/dad2.12367. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 36348972 Free PMC article.
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Mazer NA, Hofmann C, Lott D, Gieschke R, Klein G, Boess F, Grimm HP, Kerchner GA, Baudler-Klein M, Smith J, Doody RS; Alzheimer's Disease Neuroimaging Initiative. Mazer NA, et al. Among authors: hofmann c. Alzheimers Dement. 2023 Jun;19(6):2287-2297. doi: 10.1002/alz.12877. Epub 2022 Dec 1. Alzheimers Dement. 2023. PMID: 36454709
648 results